Amgen reported its second-quarter 2026 financial results, showcasing strong performance. Following this, the company raised its sales outlook by $1 billion, reflecting confidence in its growth trajectory.
Amgen has reported its financial results for the second quarter of 2026, showcasing a strong performance. Following this, the company has increased its sales outlook by $1 billion.
Amgen reported its second-quarter 2026 financial results, showcasing strong performance. Following this, the company increased its sales outlook by $1 billion.
Amgen has reported its financial results for the second quarter of 2026, showcasing strong performance. Following this success, the company has increased its sales outlook by $1 billion.
Amgen reported its financial results for the second quarter of 2026, showcasing strong performance. Following this, the company raised its sales outlook by $1 billion, reflecting confidence in its growth trajectory.
Amgen reported its financial results for the second quarter of 2026, achieving a revenue of $6.5 billion. The company highlighted continued product momentum as a key driver of its performance.
Amgen reported its second quarter 2026 financial results, showcasing an earnings beat that exceeded analysts' expectations. The company also raised its full-year outlook while announcing the discontinuation of AMG 513.
Amgen reported its second quarter 2026 financial results, showcasing an earnings beat that exceeded analysts' expectations. The company also raised its full-year outlook, signaling confidence in its performance moving forward.
Amgen Inc. raised its full-year profit and revenue forecast after the drugmaker beat Wall Street’s expectations in sales of its key medicines.
Amgen Inc. experienced a cyber incident that involved the theft of patient information and proprietary data stored in cloud servers. This incident marks the latest large healthcare company to suffer a data breach.
Chubb, Toast And A Health Care Stock On CNBC's ‘Final Trades'
Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment
Amgen second-quarter sales rise 9%, profit tops Street view
Amgen discloses data breach, says patient information was stolen
Amgen submits new data to challenge FDA's proposal to withdraw Tavneos
Amgen settles shareholder lawsuit claiming it hid $10.7 billion tax bill